A mechanistic classification of clinical phenotypes in neuroblastoma-Reference-Cited by-同舟云学术

A mechanistic classification of clinical phenotypes in neuroblastoma

Published:2018-12-07 Issue:6419 Volume:362 Page:1165-1170
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Ackermann Sandra¹²^ORCID,Cartolano Maria²³,Hero Barbara⁴^ORCID,Welte Anne¹²,Kahlert Yvonne¹²,Roderwieser Andrea¹²,Bartenhagen Christoph¹²,Walter Esther¹²,Gecht Judith⁴,Kerschke Laura⁵^ORCID,Volland Ruth⁴,Menon Roopika⁶^ORCID,Heuckmann Johannes M.⁶^ORCID,Gartlgruber Moritz⁷,Hartlieb Sabine⁷,Henrich Kai-Oliver⁷,Okonechnikov Konstantin⁸,Altmüller Janine²⁹,Nürnberg Peter²⁹¹⁰^ORCID,Lefever Steve¹¹,de Wilde Bram¹¹^ORCID,Sand Frederik¹²,Ikram Fakhera¹²¹²,Rosswog Carolina¹²,Fischer Janina¹²,Theissen Jessica¹⁴,Hertwig Falk¹²¹³¹⁴¹⁵^ORCID,Singhi Aatur D.¹⁶,Simon Thorsten⁴,Vogel Wenzel¹⁷¹⁸,Perner Sven¹⁷¹⁸,Krug Barbara¹⁹,Schmidt Matthias²⁰,Rahmann Sven²¹²²^ORCID,Achter Viktor²³,Lang Ulrich²³²⁴,Vokuhl Christian²⁵,Ortmann Monika²⁶,Büttner Reinhard²⁶,Eggert Angelika¹³¹⁴¹⁵^ORCID,Speleman Frank¹¹,O’Sullivan Roderick J.²⁷,Thomas Roman K.³¹⁴²⁶²⁸,Berthold Frank⁴,Vandesompele Jo¹¹,Schramm Alexander²⁹^ORCID,Westermann Frank⁷^ORCID,Schulte Johannes H.¹³¹⁴¹⁵²⁸,Peifer Martin²³,Fischer Matthias¹²

Affiliation:

1. Department of Experimental Pediatric Oncology, University Children’s Hospital of Cologne, Medical Faculty, Cologne, Germany.

2. Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.

3. Department of Translational Genomics, Center of Integrated Oncology Cologne–Bonn, Medical Faculty, University of Cologne, Cologne, Germany.

4. Department of Pediatric Oncology and Hematology, University Children’s Hospital of Cologne, Medical Faculty, Cologne, Germany.

5. Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.

6. NEO New Oncology GmbH, Cologne, Germany.

7. Division of Neuroblastoma Genomics (B087), German Cancer Research Center, and Hopp Children′s Cancer Center at NCT Heidelberg (KiTZ), Heidelberg, Germany.

8. Division of Pediatric Neurooncology, German Cancer Research Center, and Hopp Children’s Cancer Center at NCT Heidelberg (KiTZ), Heidelberg, Germany.

9. Cologne Center for Genomics, University of Cologne, Cologne, Germany.

10. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.

11. Center for Medical Genetics, Ghent University, Ghent, Belgium.

12. Interdisciplinary Research Centre in Biomedical Materials (IRCBM), COMSATS University Islamabad, Lahore Campus, Lahore, Pakistan.

13. Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, Berlin, Germany.

14. German Cancer Consortium (DKTK), Heidelberg, Germany.

15. Berlin Institute of Health, Berlin, Germany.

16. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

17. Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.

18. Research Center Borstel, Leibniz Center for Medicine and Biosciences, Borstel, Germany.

19. Department of Diagnostic and Interventional Radiology, University Hospital of Cologne, Cologne, Germany.

20. Department of Nuclear Medicine, University of Cologne, Cologne, Germany.

21. Genome Informatics, Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

22. Computer Science, TU Dortmund, Dortmund, Germany.

23. Computing Center, University of Cologne, Cologne, Germany.

24. Department of Informatics, University of Cologne, Cologne, Germany.

25. Kiel Pediatric Tumor Registry, Department of Pediatric Pathology, University of Kiel, Kiel, Germany.

26. Department of Pathology, University of Cologne, Cologne, Germany.

27. Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute (UPCI), Hillman Cancer Center, Pittsburgh, PA, USA.

28. German Cancer Research Center (DKFZ), Heidelberg, Germany.

29. Department of Medical Oncology, West German Cancer Center Essen, University of Duisburg-Essen, Essen, Germany.

Abstract

A systematic look at a childhood tumor Neuroblastomas—the most common tumor type in infants—develop from fetal nerve cells, and their clinical course is highly variable. Some neuroblastomas are fatal despite treatment, whereas others respond well to treatment and some undergo spontaneous regression without treatment. Ackermann et al. sequenced more than 400 pretreatment neuroblastomas and identified molecular features that characterize the three distinct clinical outcomes. Low-risk tumors lack telomere maintenance mechanisms, intermediate-risk tumors harbor telomere maintenance mechanisms, and high-risk tumors harbor telomere maintenance mechanisms in combination with RAS and/or p53 pathway mutations. Science , this issue p. 1165

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference47 articles.

1. Neuroblastoma

2. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

3. Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma

4. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

5. Telomerase activation by genomic rearrangements in high-risk neuroblastoma

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA repair and replicative stress addiction in neuroblastoma;EJC Paediatric Oncology;2024-12

2. FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma;2024-09-10

3. Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma;Journal of Personalized Medicine;2024-09-08

4. Altered methylation of imprinted genes in neuroblastoma: implications for prognostic refinement;Journal of Translational Medicine;2024-08-31

5. miR-124 in Neuroblastoma: Mechanistic Insights, Biomarker Potential, and Therapeutic Prospects;Current Proteomics;2024-08-27